²é¿´: 1045  |  »Ø¸´: 0

shenchui

½û³æ (³õÈëÎÄ̳)


[×ÊÔ´] ҽѧ¿ÆÑÐÂÛÎĵĸñʽ×ۺϰæ

¸ù¾ÝҽѧÔÓÖ¾±à¼­¹ú¼ÊίԱ»áÖÆ¶¨µÄ¡¶ÉúÎïҽѧÔÓ־Ͷ¸åͳһҪÇó¡·Ò»ÆªÉúÎïҽѧ¿ÆÑÐÂÛÎÄ£¨ÒÔϼò³Æ¡°ÂÛÎÄ¡±£©Ó¦°üÀ¨ÒÔÏÂ12¸ö²¿·Ö£º

1.±êÌâ(title)
2.ÕªÒª(abstract)
3.ÒýÑÔ(introduction)
4.²ÄÁÏÓë·½·¨(materials and methods)
5.½á¹û(results)
6.ÌÖÂÛ(discussion)
7.ÖÂл(acknowledgements)
8.²Î¿¼ÎÄÏ×(references)
9.²åͼ˵Ã÷(legends)
10.²åͼ(figures)
11.±í¸ñ(tables)
12.ÕÕÆ¬ºÍ˵Ã÷(plates and explanations)
ÒÔÉϳý7¡¢9¡¢10¡¢11¡¢12²¿·ÖÒòʵ¼ÊÇé¿ö²»ÐèÒªÍ⣬ÆäËû¸÷²¿·ÖÊÇһƪÂÛÎıز»¿ÉÉÙµÄÄÚÈÝ¡£

1¡¢ÒýÑÔ²¿·Ö
×ܵÄÒªÇó£º
˵Ã÷Ñо¿µÄ×ÜÌ巶ΧºÍÄ¿µÄ¡£
¾ßÌåÒªÇó£º
a. ±³¾°¨c˵Ã÷ËùÑо¿ÎÊÌâµÄĿǰ×ÜÌåÇé¿ö»òÀúÊ·(statement of general area or history ofproblem)£»
b. ÒâÒå¨c˵Ã÷Ñо¿µÄÒâÒå»ò±ØÒªÐÔ(statement of importance or need)£»
c.½øÕ¹¨c˵Ã÷ÓйظÃÎÊÌâµÄÏÈÓз¢ÏÖ¡¢±¨¸æ»òÑо¿(statement of previous findings,reports orstudies)¡£³ÂÊöÕⲿ·ÖÄÚÈÝʱһ°ãÒªÓÐÒýÎÄ(citations)£»
d. Ä¿µÄ¨c˵Ã÷±¾Ñо¿µÄÄ¿µÄ(statement of purpose of current study)£»
e. ·¶Î§¨c˵Ã÷ÒªÑо¿ÎÊÌâµÄ¾ßÌ巶Χ(statement of specific area of problem to bestudied)

2¡¢²ÄÁÏÓë·½·¨²¿·Ö
×ܵÄÒªÇó£º
½á¹ûµÄ¿ÉÖØÑÝÐÔ¡¢·½·¨µÄ¿É*ÐÔÒÔ¼°Ç°ºóµÄÂß¼­ÐÔ¡£
¾ßÌåÒªÇó£º
a. ¼òҪ˵Ã÷Ñо¿Éè¼Æ(study design/protocol)£¬È磺»Ø¹Ë(retrospective/review)£¬Ç°Õ°(prospective)£¬ÁÙ´²(clinical)£¬¶¯Îï(animal)£¬ÊµÑé(experimental)£¬»îÌåÄÚ(in vivo) »îÌåÍâ(in vitro)£¬Ô­Î»(in situ) Ëæ·Ã(follow-up)£¬¶ÔÕÕ(controlled)£¬Ëæ»ú(random/randomized)£¬Ë«Ã¤½»*(double- blind crossover)£¬ÈËȺ(population/cohort/migrant)£¬¶Ô±È(comparative)£¬Á÷Ðв¡Ñ§(epidemiological) µÈÑо¿ÐÔÖÊ£»
b. Ïêϸ˵Ã÷Ñо¿¶ÔÏó(subject) Çé¿ö£¬°üÀ¨Ñо¿ÈËÔ±(student)£¬±»Ñо¿µÄÈË(client) ºÍ¶¯Îï(animal) µÄÐÔ±ð(***)¡¢ÄêÁä(age)£¬ÎïÖÖ(species)£¬Æ·ÖÖ(breed) ÉúÀí״̬(physiological state)£»Î¢ÉúÎïÔòҪ˵Ã÷Æä¾úÖê(strain)£¬ÑªÇåÐÍ(serotype) ¼°ÆäËûÇø±ðÌØÐÔ(identity characteristics)£»
c. Ëæ»ú·Ö×é·Ö×é·½·¨(methods of any random assignment of subjects togroups) ºÍÑ¡Ôñ±ê×¼(criteria for admission to study groups)£»
d. Ïêϸ˵Ã÷ËùÓõÄÒ©Îï(drug)£¬¼¤ËØ(hormone)£¬ÊÔ¼Á(reagent) ºÍÆäËû»¯Ñ§Æ·(chemical) µÄÃû³Æ¡¢É̱ê(trademark)¡¢Éú²ú³§¼Ò(manufacturer)¼°ËùÔÚµØ(location)
e. ¼òҪ˵Ã÷²â¶¨·½·¨(method of measurement)£¬°üÀ¨Ãû³Æ£¬ÒýÎÄºÍÆ«²î(variations);
f. ¼òҪ˵Ã÷ͳ¼ÆÑ§·ÖÎö·½·¨(method of statistic analysis)
Õⲿ·ÖµÄ³ÂÊö³ÌÐòÒ»°ãΪ£ºÑо¿Éè¼Æ¡úÑо¿¶ÔÏóÐÔÖÊ¡ú´¦Àí/¸ÉÔ¤·½·¨¡ú²â¶¨/¹Û²ìÊֶΡúͳ¼Æ·ÖÎö¡£
³ýָʾÐÔ˵Ã÷Í⣬È磺¡°²¡ÈË×ÊÁϼû±í1¡±(data of the patients are shown in table 1) ¡°²ÄÁÏÓë·½·¨¡±ºÍ¡°½á¹û¡±Á½²¿·ÖÒ»ÂÉÓùýȥʱ±í´ï¡£

3¡¢½á¹û²¿·Ö
×ܵÄÒªÇó£º
ÈÃÑо¿µÄ¿Í¹Û½á¹û˵»°£¬²»ÒªÌíÖ¦¼ÓÒ¶¡£
¾ßÌåÒªÇó£º
a. ¶ÔËù»ñ½á¹û½øÐиÅÊö(overview of the results);
b. ˵Ã÷Ëù»ñ×ÊÁÏ»òÊý¾ÝµÄͳ¼ÆÒâÒå(statistical significance);
ͳ¼ÆÖ§³Ö(statisticalsupport)£¬°üÀ¨Í¼£¬±í£¬ÕÕÆ¬µÈ(·²ÓÃͼ±í±íʾµÄÄÚÈݲ»ÔÙÓÃÎÄ×ÖÏêÊö)¡£²»ÒªÓÃÄ£ÀâÁ½¿ÉµÄ´Ê»ò¶ÌÓï±íÊö½á¹û£¬È磺¡°theresults tended to be greater than¡­¡±¡£

4¡¢ÌÖÂÛ²¿·Ö
×ܵÄÒªÇó£º
ÓëÏÈÓÐÑо¿Ïà±È£¬±¾Ñо¿ÓкÎÒâÒå¡£
¾ßÌåÒªÇó£º
a. ¼òҪ˵Ã÷Ñо¿±³¾°(background)
b. ¼òÒª½éÉÜ×ܵķ¢ÏÖ(general findings);
c. ½éÉܾßÌåÒªµã(introduction of points)
d. ÓëÏÖÓз¢ÏÖ(ÈôÓÐ)½øÐбȽÏ(comparison in the context of other studies)
e. ÒâÒå(suggested meaning)
f. ½áÂÛ(conclusion)
g. ǰհÑо¿(future studies)
½áÂÛÍùÍùÊÇÂÛÎÄÖÐ×ҲÊÇ×îÄÑдµÄ²¿·Ö£¬Ö÷ÒªÔ­ÒòÊÇ×÷ÕßÒª¶ÔÑо¿½á¹ûºÍ·¢ÏÖ½øÐзÖÎö¡¢Íƶϡ¢ÑÝÒïºÍÍÆÀí£¬ÒªÇó×÷Õß¾ßÓкÜÇ¿Âß¼­Ë¼Î¬ÄÜÁ¦ºÍÓ¢ÓïÎÄ×Ö×éÖ¯ÄÜÁ¦¡£´ËÍ⣬Õⲿ·Öʱ̬±È½Ï¸´ÔÓ£¬Òª·ÖÇåʵÑé¹ý³ÌºÍ½á¹û(¹ýȥʱ)Óë·ÖÎöÒâ¼û(È·¶¨£ºÏÖÔÚʱ;²»È·¶¨»ò¼ÙÉ裺¹ýȥʱ)µÄÇø±ð;ËûÈËÑо¿½á¹û(¹ýȥʱ»òÏÖÔÚÍê³Éʱ)Óë±¾Ñо¿½á¹û(¹ýȥʱ)µÄÇø±ð;ÆÕ±éÊÊÓõĽáÂÛ(ÏÖÔÚʱ)ÓëÖ»ÊÊÓñ¾Ñо¿µÄ½áÂÛ(¹ýȥʱ)µÄÆä±ðµÈ¡£Òò´Ë£¬¶ÔÓÚhowever, may, might, could, would, possibly,probably, be likely to µÈ´Ê(×é)µÄʹÓÃÒÔ¼°we believe (think/consider) that, to ourknowledge, in our experience (practice) µÈ²åÈëÓïµÄʹÓþÍÏԵøñÍâÖØÒª¡£

5¡¢ÖÂл²¿·Ö
×ܵÄÒªÇó£º
ÖÂл´ÊºÍÖÂл·½Ê½±ØÐëÕ÷µÃÊÜлÈË»òµ¥Î»µÄͬÒâ¡£

6¡¢²Î¿¼ÎÄÏ×
×ܵÄÒªÇó£º
referencestyles should be specific to eachjournal,¼È£º¸ù¾Ý¸÷ÔÓÖ¾µÄ¾ßÌåÒªÇó£¬ÒòΪ¸÷ÔÓÖ¾¶Ô²Î¿¼ÎÄÏײ¿·ÖµÄ±àÅÅ˳ÐòºÍ¸ñʽ²»¾¡Í³Ò»¡£
ÏÖ½«urmsbjÒªÇóµÄ20¶àÖֲο¼ÎÄÏ×ÖÐ×î³£¼ûµÄ5ÖÖ¸ñʽÁоÙÈçÏ£º
1) vega kj,pina i,krevsky b.heart transplantation is associated with anincreased risk for pancreatobiliary disease.ann intern med 1996 jun1;124(11):980-3. [±ê×¼ÔÓÖ¾ÎÄÕÂ]
2) the cardiac society of australia and new zealand.clinical excisestress testing:safety and performance guidelines.med j aust1996;164:282-4. [×÷ÕßÊǸö×éÖ¯]
3) cancer in south africa[editorial].s afr med j 1984;84:15. [ÎÞ×÷ÕßÃû]
4) shen hm,zhang qf.risk assessment of nickel cardiogenicity andoccupational lung cancer.environ health perspect 1994;102 suppl1:275-82.[ijÔÓÖ¾Ôö¿¯]
5) browell da,lennard tw.immunologic status of the cancer patient andthe effects of blood transfusion on antitumor responses.curr opin gensurg 1993;325-33 [ÎÞÆÚÎÞ¾í]

7¡¢²åͼ˵Ã÷
×ܵÄÒªÇó£º
²åͼ˵Ã÷ÒªÁíҳ˫ÐдòÓ¡¡£µ±²åͼÖÐÓмýÍ·(arrow)¡¢·ûºÅ(symbol)¡¢Êý×Ö(number)»ò×Öĸ(letter)ʱ£¬ÒªÔÚÕⲿ·Ö(²»ÊÇÔÚ²åͼҳÉÏ)¶ÔÆä·½Ïò¡¢Î»ÖõÈ×÷³ö·Ç³£Ã÷È·µÄ˵Ã÷¡£

8¡¢²åͼ
×ܵÄÒªÇó£º
designyour figures for the appropriatereduction,¼´£º²åͼҪ°´ÔÓÖ¾µÄ°æÃæ´óС±ÈÀý½øÐÐѹËõ;²»Òª°Ñ²åͼÅijÉÕÕÆ¬¡£

9¡¢±í¸ñ
×ܵÄÒªÇó£º
atable should be a totally self-contained unit ofinformation,¼´£º±í¸ñÒª×÷Ϊһ¸ö¶ÀÁ¢µÄÐÅÏ¢µ¥Î»ÁíÒ³´òÓ¡¡£±í¸ñÒª¼òÃ÷Çå³þ£¬ÍêÕû(±êÌâ¡¢ÄÚÈݺͽÅ×¢)£¬¼´Ê¹Ö»ÓÐÒ»Õűí¸ñÒ²Òª±êtable1¡£
ÔÚÂÛÎÄд×÷ÉÏ»¹ÓÐʲô²»¶®µÃ¿ÉÒÔ¿´¸½¼þÊÓÆµ£¬Ò»¹²ÓÐ26¸öÊÓÆµ¿ÉÒÔѧϰ£¬¿ÉÒÔÈÃÄã¸üÖ±¹ÛµÄѧϰ~ҽѧ¿ÆÑÐÂÛÎĵĸñʽ×ۺϰæ


ҽѧ¿ÆÑÐÂÛÎĵĸñʽ×ۺϰæ-1


ҽѧ¿ÆÑÐÂÛÎĵĸñʽ×ۺϰæ-2
»Ø¸´´ËÂ¥

» ±¾Ìû¸½¼þ×ÊÔ´Áбí

  • »¶Ó­¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
    ±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com
  • ¸½¼þ 1 : 26¸öSCIд×÷½Ì³Ì.docx
  • 2019-05-22 11:16:00, 68.88 K

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ shenchui µÄÖ÷Ìâ¸üÐÂ
¡î ÎÞÐǼ¶ ¡ï Ò»ÐǼ¶ ¡ï¡ï¡ï ÈýÐǼ¶ ¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] »¯Ñ§0703Çóµ÷¼Á ѧ˶ Àí/¹¤¿Æ¾ù¿É ×Ü·Ö279 +3 1Ò»11 2026-03-03 4/200 2026-03-03 11:49 by Iveryant
[¿¼ÑÐ] ²ÄÁÏÀ࿼Ñе÷¼Á +6 gemmgemm 2026-03-01 7/350 2026-03-03 11:16 by EBSD
[»ù½ðÉêÇë] ûÓÐÇà»ùÖ±½ÓÉêÇëÃæÉÏ£¬¸Ð¾õ×Ô¼º·èÁË +3 kevin63t 2026-03-02 4/200 2026-03-03 11:10 by celinswift
[ÂÛÎÄͶ¸å] ͨѶ×÷Õßд˭£¬ÎÊÌâÊÇÄãÒâÏë²»µ½µÄÎÊÌâ 15+3 °¢¶û·¨°¡ 2026-03-01 3/150 2026-03-03 09:13 by ±±¾©À³ÒðÈóÉ«
[¿¼ÑÐ] Ç廪´óѧ ²ÄÁÏÓ뻯¹¤ 353·ÖÇóµ÷¼Á +5 awaystay 2026-03-02 6/300 2026-03-03 09:03 by houyaoxu
[¿¼ÑÐ] Àíѧ£¬¹¤Ñ§£¬Å©Ñ§µ÷¼Á£¬ÉÙ×ßÍä·£¬ÕâÀï»¶Ó­Äú£¡ +6 likeihood 2026-03-02 9/450 2026-03-03 08:29 by lfy760306
[¿¼ÑÐ] 0856²ÄÁÏÓ뻯¹¤£¬270Çóµ÷¼Á +11 YXCT 2026-03-01 13/650 2026-03-02 21:38 by sunny81
[¿¼²©] ²©Ê¿×Ô¼ö +4 kkluvs 2026-02-28 5/250 2026-03-02 19:19 by ÇáËɲ»ÉÙËæ
[¿¼ÑÐ] 284Çóµ÷¼Á +5 ÌìÏÂŸß 2026-03-02 5/250 2026-03-02 18:38 by caszguilin
[¿¼ÑÐ] һ־Ըɽ¶«´óѧ²ÄÁÏÓ뻯¹¤325Çóµ÷¼Á +5 °ë½ØµÄÊ«0927 2026-03-02 5/250 2026-03-02 18:37 by Ã÷ÁÁ9527
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤328Çóµ÷¼Á +3 ¡££¬¡££¬¡££¬¡£i 2026-03-02 3/150 2026-03-02 13:09 by houyaoxu
[¿¼ÑÐ] 291 Çóµ÷¼Á +3 »¯¹¤2026½ì±ÏÒµÉ 2026-03-02 3/150 2026-03-02 12:55 by houyaoxu
[¿¼ÑÐ] 265·ÖÇóµ÷¼Á²»µ÷רҵºÍѧУÓÐÐÐѧÉÏ¾Í +6 ÀñÌö¡Õæ258 2026-02-28 9/450 2026-03-02 12:04 by 52hz~~
[»ù½ðÉêÇë] ´Ë³É¹û²»Äܵ¼ÈëÔ­Òò£ºÔªÊý¾Ý±ØÌîÐÅÏ¢²»ÍêÕû£¬¿É ½øÐв¹³ä¡£ +4 Kittylucky 2026-03-02 5/250 2026-03-02 11:07 by jurkat.1640
[¿¼ÑÐ] 275Çóµ÷¼Á +3 L-xin? 2026-03-01 6/300 2026-03-02 10:22 by ÈÈÇéɳĮ
[»ù½ðÉêÇë] ±¾×ÓдÍêÁË£¬¸øDSÐֵܿ´ÁË£¬µÃÁË92·Ö +3 Doma 2026-03-01 7/350 2026-03-02 00:00 by jnzsy
[˶²©¼ÒÔ°] ²©Ê¿×Ô¼ö +7 ¿ÆÑй·111 2026-02-26 11/550 2026-03-01 22:24 by ÕÜÆ½L
[¿¼ÑÐ] »¯¹¤299·ÖÇóµ÷¼Á Ò»Ö¾Ô¸985Âä°ñ +5 ÎûÎû(*^¦Ø^*) 2026-03-01 5/250 2026-03-01 19:47 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 291·Ö¹¤¿ÆÇóµ÷¼Á +9 science¶ö¶ö 2026-03-01 10/500 2026-03-01 18:55 by 18137688336
[¿¼ÑÐ] µ÷¼Á +3 ¼òľChuFront 2026-02-28 3/150 2026-03-01 11:46 by ÍõΰҪÉϰ¶°¡
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û